BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Grant

Awarded By

Total Award Amount

  • 28636.00

    • Direct Costs

  • 19284.00

    • Sponsor Award Id

  • 10022

    • Contributor

  • Racquel Innis-Shelton M.D.   Principal Investigator